Resultados del primer bimestre de trabajo de la unidad de diagnóstico COVID-19 de la Facultad de Ciencias Veterinarias-UNLP

Analecta Veterinaria Pub Date : 2020-10-28 DOI:10.24215/15142590e050

Gastón Moré, Carlos Javier Panei, N. Fuentealba, C. Aspitia, M. E. Bravi, Javier Origlia, Magdalena Rambeaud, M. Tizzano, Gabriela Rudd Garcés, C. Golijow, J. M. Unzaga, Marcelo Pecoraro

{"title":"Resultados del primer bimestre de trabajo de la unidad de diagnóstico COVID-19 de la Facultad de Ciencias Veterinarias-UNLP","authors":"Gastón Moré, Carlos Javier Panei, N. Fuentealba, C. Aspitia, M. E. Bravi, Javier Origlia, Magdalena Rambeaud, M. Tizzano, Gabriela Rudd Garcés, C. Golijow, J. M. Unzaga, Marcelo Pecoraro","doi":"10.24215/15142590e050","DOIUrl":null,"url":null,"abstract":"The COVID-19 pandemic required rapid development and approval of diagnostic methods and kits. Nasal swab samples (n=1114) were derived to Faculty of Veterinary Sciences- UNLP COVID-19 diagnostic unit by the Buenos Aires Province Ministry of Health during June and July 2020, to perform molecular diagnosis of SARS- CoV-2. Samples of RNA were purified in a type II biosafety cabin and analyzed by real time RT-PCR with the GeneFinder™ kit, which amplifies 3 viral target genes (N, E y RdRp). Of the 1110 samples with positive internal control, 458 (41.2%) were positive (26.9% to all target genes, 4.2% to 2 target genes and almost 10% to one gene, mainly N). Percentage of positive samples remained similar throughout the study period, although the sample number was higher in July (781 samples; 315 positive) compared to June (333 samples; 143 positive). Samples from Berisso, Ensenada and La Plata had significantly lower positive rate than those coming from other counties (27.6% versus 60.7%, respectively). Positivity rate was higher in samples from patients with ≥3 clinical signs (55.6%). It is necessary to conduct inter-laboratory validation studies and standardization of diagnostic methods used in order to obtain reliable and reproducible results.","PeriodicalId":7773,"journal":{"name":"Analecta Veterinaria","volume":"40 1","pages":"050-050"},"PeriodicalIF":0.0000,"publicationDate":"2020-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Analecta Veterinaria","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24215/15142590e050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

The COVID-19 pandemic required rapid development and approval of diagnostic methods and kits. Nasal swab samples (n=1114) were derived to Faculty of Veterinary Sciences- UNLP COVID-19 diagnostic unit by the Buenos Aires Province Ministry of Health during June and July 2020, to perform molecular diagnosis of SARS- CoV-2. Samples of RNA were purified in a type II biosafety cabin and analyzed by real time RT-PCR with the GeneFinder™ kit, which amplifies 3 viral target genes (N, E y RdRp). Of the 1110 samples with positive internal control, 458 (41.2%) were positive (26.9% to all target genes, 4.2% to 2 target genes and almost 10% to one gene, mainly N). Percentage of positive samples remained similar throughout the study period, although the sample number was higher in July (781 samples; 315 positive) compared to June (333 samples; 143 positive). Samples from Berisso, Ensenada and La Plata had significantly lower positive rate than those coming from other counties (27.6% versus 60.7%, respectively). Positivity rate was higher in samples from patients with ≥3 clinical signs (55.6%). It is necessary to conduct inter-laboratory validation studies and standardization of diagnostic methods used in order to obtain reliable and reproducible results.

查看原文本刊更多论文

兽医科学学院新冠病毒19诊断单元第一次双月工作结果

COVID-19大流行需要快速开发和批准诊断方法和试剂盒。在2020年6月和7月期间，布宜诺斯艾利斯省卫生部将鼻拭子样本(n=1114)提取至兽医科学学院- UNLP COVID-19诊断单元，以对SARS- CoV-2进行分子诊断。RNA样品在II型生物安全舱中纯化，并使用GeneFinder™试剂盒进行实时RT-PCR分析，该试剂盒扩增3个病毒靶基因(N, E和RdRp)。1110份内控阳性样品中，458份(41.2%)呈阳性，其中全部靶基因阳性26.9%，2个靶基因阳性4.2%，1个靶基因阳性近10%，以N基因为主。在整个研究期间，阳性样品的比例基本保持一致，但7月份的样本数较高(781份;315例阳性)，而6月(333例;143积极)。来自贝里索、恩塞纳达和拉普拉塔的样本阳性率明显低于其他县(分别为27.6%和60.7%)。≥3个临床症状的患者标本阳性率较高(55.6%)。为了获得可靠和可重复的结果，有必要对所使用的诊断方法进行实验室间验证研究和标准化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊